The global companion animal diagnostics market size was estimated at USD 6.35 billion in 2024 and is projected to reach USD 11.03 billion by 2030, growing at a CAGR of 9.66% from 2025 to 2030. The rising trend of pet ownership across major markets such as the United States, Brazil, and China has significantly accelerated the demand for advanced veterinary care.
Pet owners are placing greater emphasis on early disease detection, preventive healthcare measures, and personalized treatment protocols tailored to individual animals. This growing focus is largely driven by the increasing incidence of zoonotic diseases that can be transmitted from animals to humans, underscoring the need for robust animal health management. As a result, veterinary diagnostics have emerged as a critical component in the healthcare continuum, enabling veterinarians to identify illnesses at earlier stages, implement timely interventions, and ensure better health outcomes for companion animals while also protecting public health. Some of the key factors accounting for market growth include increased expenditure on animal health, rising incidence of diseases in animals, advancements in diagnostics, and growing medicalization rate.
Moreover, in September 2024, Zoetis introduced the Vetscan OptiCell, an innovative, AI-powered, cartridge-based hematology analyzer designed to provide laboratory-grade complete blood count (CBC) results directly at the point of care. This next-generation diagnostic tool enhances clinical accuracy, streamlines workflow efficiency, and features a compact, user-friendly design tailored for veterinary practices. The device is set to make its public debut at the London Vet Show in November 2024.
This cutting-edge innovation is poised to significantly drive growth in the companion animal diagnostics industry. By enabling rapid, reliable, and on-site blood analysis, Vetscan OptiCell empowers veterinarians to make faster and more informed treatment decisions. The integration of AI not only boosts diagnostic precision but also reduces the need for outsourced lab services, thereby lowering turnaround time and operational costs. As veterinary clinics and hospitals increasingly seek advanced, easy-to-use diagnostic tools that deliver immediate results, demand for such point-of-care solutions is expected to rise, contributing to broader market expansion. In addition, the launch strengthens Zoetis' leadership position in veterinary diagnostics, encouraging further innovation and investment in the sector.
Product |
Company |
Product Information |
ASP (USD) |
VetScan HM5 |
Zoetis |
Veterinary Hematology Analyzer |
6,800 per unit |
VETSCAN VS2 Chemistry Analyzer |
Zoetis |
Veterinary chemistry analyzer |
2,200 to 6,800 per unit |
IDEXX Catalyst One |
IDEXX Laboratories |
Veterinary chemistry analyzer |
14,995 per unit |
LaserCyte Dx |
IDEXX Laboratories |
Veterinary Hematology Analyzer |
4,500 per unit |
Test Kits |
- |
Consumables, Reagents & Kits |
1.20 to 7.80 |
Source: Secondary Research, Grand View Research
Test Type |
ASP (USD) |
Cat FeLV/FIV Combo Test |
40 |
Dog Heartworm Test |
40 |
Dog Heartworm Test |
50 |
Source: Secondary Research, Grand View Research
The increasing prevalence of zoonotic diseases transmissible from animals to humans is significantly driving growth in the market for companion animal diagnostics. As public health risks rise, there is a growing demand for early detection and accurate diagnosis of these diseases in animals to prevent potential outbreaks and ensure both animal and human safety. This has led to greater adoption of advanced diagnostic tools, such as molecular tests and point-of-care analyzers, across veterinary clinics, farms, and diagnostic laboratories. In addition, heightened awareness of the One Health approach, which recognizes the link between human, animal, and environmental health, is prompting increased investments in veterinary disease surveillance and preventive care. Together, these factors are propelling the expansion of the veterinary diagnostics industry.
The companion animal diagnostics industry is defined by several influential characteristics that shape its growth trajectory and structural dynamics. The integration of diagnostics with information technology, such as cloud-based data sharing platforms, enhances workflow efficiency and facilitates better treatment planning. The ongoing development of faster, more precise assays, including PCR-based molecular tests and advanced immunoassays, reflects the industry's commitment to improving diagnostic capabilities. These innovations collectively contribute to a highly dynamic and competitive market landscape.
The market is also experiencing a significant wave of mergers and acquisitions (M&A), as established players pursue strategic partnerships or acquire smaller firms to enhance their product offerings, gain access to advanced technologies, and reinforce their market position. For instance, in September 2023,Mars, Incorporated acquired SYNLAB Vet from SYNLAB Group, now integrating it into Mars Petcare's Science & Diagnostics division. This strategic move enhances diagnostic capabilities, accelerates R&D, and expands global access to pet healthcare solutions, fostering a shared commitment to creating a better world for pets.
The market offers a diverse array of tools and modalities that can serve as alternatives to one another, depending on clinical needs, cost considerations, and accessibility. For example, traditional diagnostic methods such as physical examinations, microscopy, and basic in-house lab tests may act as substitutes for more sophisticated technologies like molecular diagnostics or imaging equipment in routine or less critical cases. Similarly, the emergence of point-of-care testing (POCT) devices presents a key substitution trend.
Companies in the market frequently pursue regional expansion strategies to increase their market reach. This approach involves entering new geographic areas to capitalize on emerging opportunities, access a broader customer base, and cater to the distinct needs of various regions. Success in these markets often requires tailoring products and strategies to align with local preferences, regulatory frameworks, and specific animal healthcare demands. Customizing diagnostic solutions to address the unique characteristics of each region is essential for effective expansion.
By testing category, the clinical chemistry segment dominated the market with a share of 23.20% in 2024, due to its critical role in evaluating the health status of animals through the analysis of blood and other bodily fluids. It enables the detection of metabolic disorders, organ function abnormalities, and various diseases, making it indispensable in routine and preventive veterinary care. For example, liver and kidney function tests using clinical chemistry analyzers help veterinarians diagnose conditions early and monitor treatment effectiveness in pets. The growing demand for rapid, accurate diagnostics in both companion and farm animals further reinforces the dominance of clinical chemistry in the market.
The cytopathology segment is anticipated to grow at the fastest CAGR of 13.55% over the coming years. This technique is widely used for identifying infections, inflammatory conditions, and various cancers in animals through minimally invasive procedures like fine needle aspiration. For example, veterinarians often use cytopathology to examine skin lumps or lymph node swellings in dogs and cats to determine if they are benign or malignant. The increasing demand for precise, rapid diagnostics in animal healthcare significantly boosts the adoption of cytopathology, thereby propelling market growth.
Based on animal, the dogs segment held the largest market share in 2024. The growing dog population, expenditure on pets, pet humanization, medicalization rate, and uptake of pet insurance are some of the key drivers of the segment. For instance, according to the National Pet Owners Survey 2023-2024 conducted by the American Pet Products Association, 86.9 million households (around 66%) in the U.S. owned dogs. For decades, dogs have gained greater importance and popularity in North America, where owners frequently treat them as devoted family members. To a degree, where one-third of the U.S. population loves their dogs more than their partners.
The others segment is expected to register the fastest CAGR from 2025 to 2030. The growing population and rising health awareness of other companion animals, such as rabbits, guinea pigs, reptiles, and birds, significantly drive the veterinary diagnostic products market by expanding the demand beyond traditional pets such as cats and dogs. Owners of these animals increasingly seek specialized diagnostic services to ensure their pets’ well-being, prompting the development and adoption of tailored diagnostic tools. For example, reptiles require specific blood chemistry and parasite testing to detect health issues unique to their species. This diversification in companion animal care fuels market growth as manufacturers innovate to meet the varied diagnostic needs of these less common pets.
In terms of product, the consumables, reagents & kits segment held the largest market share in 2024, due to their critical role in enabling efficient, accurate, and cost-effective testing. Unlike expensive diagnostic instruments that require significant upfront investment and maintenance, consumables and kits offer a more accessible solution for veterinary clinics of all sizes. These products include items such as test strips, reagents, slides, and ready-to-use kits that simplify complex diagnostic processes, allowing veterinarians to quickly detect common diseases and monitor animal health. For example, rapid antigen test kits for canine parvovirus or feline leukemia virus provide results within minutes, facilitating timely treatment decisions and improving animal outcomes without the need for specialized equipment or extensive training.
Moreover, consumables and reagents offer greater flexibility and convenience compared to standalone diagnostic instruments. They can be easily stocked, transported, and used in various clinical settings, including mobile or remote veterinary services, which is increasingly important as pet owners seek more accessible healthcare for their companion animals. In addition, these products can be tailored for specific diagnostic needs, ensuring higher sensitivity and specificity for particular diseases or conditions common in cats, dogs, and other pets. This adaptability, combined with their cost-effectiveness and ease of use, makes consumables, reagents, and kits the preferred choice for many veterinarians, thereby driving their dominance in the market over larger, more complex instruments.
By end use, the veterinarians segment held the largest share of the market in 2024. This segment traditionally holds the largest market share because they are the primary user and decision-makers driving demand for diagnostic tools and services. Their expertise in diagnosing and treating a wide range of health conditions in pets, such as dogs, cats, and other companion animals, makes them essential stakeholders in adopting advanced diagnostic technologies. For example, veterinarians routinely rely on blood chemistry analyzers, rapid test kits, and imaging devices to accurately diagnose illnesses like kidney disease or infections in pets, guiding timely treatment plans. Their growing emphasis on preventive care and early disease detection continues to boost the use of diagnostic products, reinforcing their pivotal role in shaping market growth.
The animal owners segment is estimated to grow at the fastest CAGR in the coming years. As pet owners become more aware of the importance of regular health check-ups and early disease detection, they actively seek advanced diagnostic services to ensure the well-being of their animals. For example, a dog owner may insist on routine blood tests and screenings for conditions such as diabetes or thyroid disorders to catch problems early and improve treatment outcomes. This growing commitment to proactive and preventive care by animal owners directly fuels the demand for diagnostic products, making them key influencers in the market’s expansion.
The North America companion animal industry held the largest revenue share of 38.25% in 2024. This growth was augmented by the presence of major animal diagnostics companies and the increasing companion animal population. These companies engage in strategic initiatives to drive market growth. For example, in September 2023, Embark Veterinary formed a partnership with Assistance Dogs International (ADI) to offer DNA testing kits to ADI’s breeding cooperative members across North America. This collaboration enables screening for more than 250 genetic health conditions in assistance dogs, promoting healthier breeding practices and extending the service life of these dogs. Similarly, partnerships like Embark Veterinary with ADI and Mars Petcare’s collaboration with the Broad Institute are anticipated to improve access to genetic testing and advance research capabilities in the field.
The U.S. companion animal diagnostics industry is growing rapidly due to the rise in technological advancements to enhance early disease detection and personalized treatment options for pets, along with the presence of key market players. For example, in May 2025, Zoetis Inc., a global leader in animal health, unveiled its newest and largest diagnostics reference laboratory at the UPS Healthcare Labport facility located at Louisville Muhammad Ali International Airport. The ribbon-cutting ceremony was attended by Kentucky Governor Andy Beshear and other state officials. This strategic expansion marks a major milestone in Zoetis’ continued commitment to innovation in diagnostics, designed to enhance animal care by providing veterinarians and pet owners throughout the United States with faster, more accurate, and more accessible testing services.
The European companion animal diagnostics industry is influenced by several trends.The region has a high rate of pet ownership, with growing awareness among pet owners about the importance of preventive healthcare and early disease detection. This increased demand for advanced diagnostic services pushes veterinary clinics and hospitals to adopt innovative testing technologies. In addition, Europe’s stringent animal health regulations and emphasis on animal welfare encourage the use of precise diagnostic tools to ensure proper disease management and control. For example, countries such as Germany, France, and the UK have well-established veterinary infrastructures and government initiatives supporting animal health, which further stimulate market expansion.
France companion animal diagnostics industry is anticipated to grow swiftly due to the increasing uptake of pet insurance. The demand for insurance coverage is increasing as more homes are getting dogs. Furthermore, the need for pet insurance is highlighted by the ongoing increase in veterinary costs, which is linked to improvements in treatment and rising veterinary service costs, including diagnostics. This insurance protects pet owners from unexpected medical bills, encouraging them to prioritize their pets' health by purchasing insurance coverage. Pet insurance policies in France range from USD 8.61 to USD 10.79 per month.
The Asia Pacific companion animal diagnostics industry is projected to experience substantial growth over the forecast period, propelled by several influential factors. A major driver is the significant investment in research and development by leading global companies, which fuels innovation and the introduction of advanced diagnostic solutions tailored for the region. These efforts are complemented by ongoing initiatives to commercialize pet disease diagnostic services at more affordable price points, making these technologies increasingly accessible to a broader customer base. Furthermore, the region faces a pressing need to manage frequent disease outbreaks, and the rising incidence of zoonotic disease illnesses transmitted between animals and humans, which heightens the demand for effective diagnostic tools. This combination of heightened health concerns and strategic investments is expected to significantly accelerate the expansion of the veterinary diagnostics market throughout Asia Pacific in the coming years.
The companion animal diagnostics industry in India is currently experiencing notable and sustained growth, driven by several key factors. One of the primary contributors is the increasing adoption of advanced diagnostic technologies, particularly PCR-based techniques, which enable early and accurate detection of diseases in companion animals such as dogs, cats, and other pets. This technological advancement allows veterinarians to diagnose and treat illnesses more effectively, improving overall animal health outcomes. In addition, there is a growing emphasis on animal healthcare across the country, with more pet owners becoming aware of the importance of preventive care and regular health monitoring for their animals. This rising awareness is fueling demand for sophisticated diagnostic services.
Latin America companion animal diagnostics industry drives the growth of the veterinary diagnostic products market through several dynamic factors, including rising pet ownership, increasing awareness about animal health, and expanding veterinary infrastructure. In countries like Brazil and Mexico, a growing middle class with higher disposable incomes is investing more in the health and wellness of their companion animals, leading to greater demand for advanced diagnostic services. For example, Brazil’s large population of pet owners has contributed to a surge in the use of diagnostic tools such as blood chemistry analyzers and rapid test kits for common diseases like canine ehrlichiosis and feline leukemia.
Brazil companion animal diagnostics industry is witnessing significant growth, increasing pet ownership, and rising awareness of animal health. Brazil, which boasts the largest pet population in Latin America, offers a vibrant and rapidly expanding market for veterinary diagnostics. The market's growth is primarily driven by the rising humanization of pets, increasing expectations for high-quality veterinary care, and escalating spending on pet health. These factors have amplified the demand for precise and timely diagnostic solutions that aid in early disease detection and preventive healthcare. In addition, the growing number of veterinary clinics throughout the country has led to increased utilization of diagnostic technologies such as blood analyzers, rapid testing kits, and advanced imaging tools, all of which are contributing significantly to the market’s expansion.
The companion animal diagnostics industry in the Middle East and Africa is experiencing notable growth, fueled by increased investments in veterinary healthcare infrastructure and the rising adoption of advanced diagnostic technologies. Countries such as South Africa and the UAE are at the forefront of this trend, with growing expenditures on veterinary services and diagnostic equipment. This surge in investment and modernization highlights the region’s evolving approach to animal healthcare and is expected to further accelerate market expansion in the coming years.
The companion animal diagnostics industry in South Africa is experiencing robust growth, largely fueled by a surge in product launches from local companies. These domestic players are developing innovative diagnostic solutions tailored to the specific needs of South African pet owners. For instance, companies such as EasyDNA South Africa and International Biosciences South Africa have introduced breed identification and health screening tests that offer affordable access to genetic diagnostics. These tools enable pet owners to determine breed composition and assess potential genetic health risks, supporting more informed decisions about their pets' care.
The companion animal diagnostics industry is highly competitive, with key players such as IDEXX Laboratories, Zoetis Inc., Heska Corporation (now part of Mars, Inc.), and Thermo Fisher Scientific holding significant market shares. These companies are actively engaging in strategic moves such as mergers, acquisitions, partnerships, and geographic expansions to reinforce their competitive positions. The presence of emerging regional players and increased investments in R&D are intensifying market competition and shaping the market dynamics.
The following are the leading companies in the companion animal diagnostics market. These companies collectively hold the largest market share and dictate industry trends.
In July 2024, EKF Diagnostics launched the Biosen C-Line, an advanced glucose and lactate analyzer designed for enhanced usability. It features a touch screen and advanced connectivity options to integrate seamlessly with hospital and lab IT systems via EKF Link. This benchtop analyzer provides highly precise glucose and lactate measurements, used in clinical settings for diabetes management and by elite sports teams for tracking lactate production in training.
In September 2024, Zoetis Inc. introduced Vetscan OptiCell, a new cartridge-based hematology analyzer that employs AI-powered technology to deliver precise Complete Blood Count (CBC) analysis at the point of care, offering lab-quality results with time, cost, and space efficiencies for veterinary clinics.
In February, 2024, MiDOG Animal Diagnostics introduced an advanced All-in-One Diagnostic Test capable of rapidly detecting bacterial and fungal infections, including antibiotic resistance, across various animal species. This innovation aims to enhance veterinary care by replacing traditional testing methods with efficient molecular-based diagnostics, supporting comprehensive treatment strategies for diverse animals, from pets to exotic species.
Report Attribute |
Details |
Market size value in 2025 |
USD 6.95 billion |
Revenue forecast in 2030 |
USD 11.03 billion |
Growth Rate |
CAGR of 9.66% from 2025 to 2030 |
Base year for estimation |
2024 |
Historical data |
2018 - 2023 |
Forecast period |
2025 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
Report Coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments Covered |
Product, testing category, animal, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
IDEXX Laboratories, Inc.; Zoetis; Antech Diagnostics, Inc. (Mars Inc.); Agrolabo S.p.A.; Embark Veterinary, Inc.; Esaote SPA; Thermo Fisher Scientific, Inc.; Innovative Diagnostics SAS; Virbac; FUJIFILM Corporation |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global companion animal diagnostics market report based on product, animal, testing category, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Consumables, Reagents & Kits
Equipment & Instruments
Testing Category Outlook (Revenue, USD Million, 2018 - 2030)
Clinical Chemistry
Microbiology
Parasitology
Histopathology
Cytopathology
Hematology
Immunology & Serology
Imaging
Molecular Diagnostics
Other Categories
Animal Outlook (Revenue, USD Million, 2018 - 2030)
Dogs
Cats
Horses
Other Companion Animals
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Reference Laboratories
Veterinarians
Animal Owners
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Norway
Sweden
Rest of Europe
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
South Africa
Saudi Arabia
Kuwait
UAE
Rest of MEA
b. The global companion animal diagnostics market size was estimated at USD 6.35 billion in 2024 and is expected to reach USD 6.95 billion in 2025.
b. The global companion animal diagnostics market is expected to grow at a compound annual growth rate of 9.66% from 2025 to 2030 to reach USD 11.03 billion by 2030.
b. North America dominated the companion animal diagnostics market with a share of 38.25% in 2024. This is attributable to favorable healthcare structure and rising government initiatives.
b. Some key players operating in the companion animal diagnostics market include IDEXX Laboratories, Inc.; Zoetis; Antech Diagnostics, Inc. (Mars Inc.); Agrolabo S.p.A.; Embark Veterinary, Inc.; Esaote SPA; Thermo Fisher Scientific, Inc.; Innovative Diagnostics SAS; Virbac; FUJIFILM Corporation
b. Key factors that are driving the companion animal diagnostics market growth include prevalence of chronic diseases demanding effective diagnostics in pet animals and rising number of pet owners indicating increased adoption of companion animals.
NEED A CUSTOM REPORT?
We offer custom report options, including stand-alone sections and country-level data. Special pricing is available for start-ups and universities.
Request CustomizationWe are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."